louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01345734: Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
Official title: Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2011-05-02
Enrollment: 1056
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult subjects with type 2 diabetes, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than liraglutide.

Brief summary: This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.


Eligibility criteria: Inclusion Criteria:

* Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician
* Subjects who are capable of giving study-specific signed informed consent before any collection of information

Exclusion Criteria:

* Subjects with type 1 diabetes
* Subjects who are or have previously been on liraglutide
* Subjects who are participating in another clinical trial
* Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
* Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

Primary outcomes:
measure: Incidence of serious adverse drug reactions (SADRs)
timeFrame: Week 0, week 26
Secondary outcomes:
measure: Incidence of adverse drug reactions (ADRs)
timeFrame: Week 0, week 26
measure: Incidence of serious adverse events (SAEs)
timeFrame: Week 0, week 26
measure: Frequency of hypoglycaemic episodes
timeFrame: Week 0, week 26
measure: Change in HbA1c (glycosylated haemoglobin)"
timeFrame: Week 0, week 26
Other outcomes:
Locations:
city: Manilla
country: Philippines
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Jimeno C, Kho S, de Los Santos GK, Buena-Bobis N, Villa M. The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes. J ASEAN Fed Endocr Soc. 2018;33(2):114-123. doi: 10.15605/jafes.033.02.02. Epub 2018 Oct 9.
Clinical trial NCT02779634: Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction
Official title: The Effect of Ubiquinol Treatment on Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Heart Failure
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2016-05-20
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are no studies specifically examining the effects of coenzyme Q (CoQ) treatment on echocardiographic indices of diastolic function in elderly patients with heart failure with preserved ejection fraction (HFPEF). In previous studies the only echocardiographic parameters studied were ejection fraction (EF) and chamber size. The objective of the proposed current study is to examine the effect of 16 weeks of ubiquinol therapy on diastolic function assessed by echocardiography in patients over the age of 50 with a clinical diagnosis of HFPEF. Ubiquinol (Kaneka Pharma), the reduced form of CoQ will be utilized for this study as it has been shown to have superior bioavailability when compared to oxidized CoQ.


Eligibility criteria: Inclusion Criteria:

* Typical signs and symptoms of congestive heart failure (CHF) (New York Association Class 2-4).
* Normal ejection fraction on echocardiography (EF ≥50%).
* Evidence of diastolic dysfunction on non-invasive imaging (E:e' \> 15 or e:e' \> 8 with other measures of diastolic dysfunction such as e/a \< 0.5 with elevated deceleration time or left atrial volume index \> 40 cc/m2 or presence of elevated left ventricular mass index or elevated pulmonary pressures).
* Stable medical therapy for 4 weeks prior to randomization

Exclusion Criteria:

* Chronic atrial fibrillation.
* Acute coronary syndrome or coronary revascularization within 60 days.
* Clinically significant valvular disease.
* Known infiltrative cardiomyopathy (e.g. amyloidosis), hypertrophic cardiomyopathy or chronic pericardial disease.
* Inability/refusal to provide informed consent

Primary outcomes:
measure: Change in diastolic function as assessed by mitral valve inflow and tissue Doppler velocities on echocardiography
timeFrame: 4 months
measure: NT-pro brain natriuretic peptide (NT-proBNP) serum levels (pg/ml)
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hadassah Medical Organization
name: David Leibowitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Samuel TY, Hasin T, Gotsman I, Weitzman T, Ben Ivgi F, Dadon Z, Asher E, Amir O, Glikson M, Alcalai R, Leibowitz D. Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Drugs R D. 2022 Mar;22(1):25-33. doi: 10.1007/s40268-021-00372-1. Epub 2021 Nov 26.
Clinical trial NCT04408534: Bilevel Noninvasive Ventilation in Infants With Bronchiolitis Presenting With Apnea
Official title: Bilevel Noninvasive Ventilation in Infants With Bronchiolitis Presenting With Apnea
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bronchiolitis
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2020-05-29
Enrollment: 20
Sex: ALL
Minimum age (years): 3
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This physiological study aims to compare Bilevel Positive Airway Pressure and continuons positive airway pressure in infants with severe bronchiolitis presenting with apnea

Detailed description: This study is a cross over randomized study which aims to compare the effect of 2 modes of noninvasive ventilation on the occurence of central apnea, as measured by electrical activity of the diaphragm

Eligibility criteria: Inclusion Criteria:

* Children born at gestational age \> 36 weeks gestation
* Ventilated in Non Invasive Ventilation (NIV) for acute bronchiolitis (clinical criteria of the American Academy of Pediatrics)
* Having presented at least 1 apnea objectified by the parents or by a health care professional, as previously described (1), with one or more of the following characteristics: 1/Associated with bradycardia \< 80 / min, 2/Associated with desaturation \< 85% or 3/Duration more than 10 seconds
* Informed consent signed by at least one of the two parents + oral agreement from the second parent before the intervention of the study (2nd signature to be collected as soon as possible)

Exclusion Criteria:

* With chronic respiratory insufficiency requiring home ventilation (NIV or under long-term oxygen therapy, initiated at least 14 days before the start of the study)
* Ventilated in NIV for more than 48 hours before inclusion
* Hemodynamically significant cardiac disease, primary ENT or pulmonary pathology (malformative or genetic) or neuromuscular pathology
* Presenting a contraindication of a gastric tube (trauma or recent surgery concerning the cervical, pharyngeal or esophageal regions, severe coagulation disorders)
* Patient not affiliated to health care insurance

Primary outcomes:
measure: Apnea
timeFrame: Up to 12 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03573934: Gut Hormones and Bone Remodeling in Humans (KS-2)
Official title: Investigation of GLP-2 Mechanism of Action (KS-2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: Hvidovre University Hospital
First posted: 2018-06-29
Enrollment: 10
Sex: MALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Effects of GLP-2 and GIP on bone remodeling in healthy young men.

Detailed description: We will investigate acute effects of GLP-2 and GIP on bone remodeling in healthy young men.

Eligibility criteria: Inclusion Criteria:

Age between 20 and 40 years old Caucasian Healthy BMI between 18.5 and 24.9 kg/m2.

Exclusion Criteria:

Chronic disease Smoking Medication Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb\<8,0 mmol/L Decreased renal function.

Primary outcomes:
measure: Bone resorption
timeFrame: From -10 minutes to 240 minutes.
measure: Bone formation
timeFrame: From -10 minutes to 240 minutes.
Secondary outcomes:
measure: Parathyroid hormone
timeFrame: From -10 minutes to 240 minutes.
measure: Calcium
timeFrame: From -10 minutes to 240 minutes.
measure: GIP
timeFrame: From -10 minutes to 240 minutes.
measure: GLP-2
timeFrame: From -10 minutes to 240 minutes.
measure: Glucose
timeFrame: From -10 minutes to 240 minutes.
measure: Insulin
timeFrame: From -10 minutes to 240 minutes.
measure: C-peptide
timeFrame: From -10 minutes to 240 minutes.
measure: Sclerostin
timeFrame: From -10 minutes to 240 minutes.
Other outcomes:
measure: Heart rate
timeFrame: From -10 minutes to 240 minutes.
measure: Blood pressure
timeFrame: From -10 minutes to 240 minutes.
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
References:
Clinical trial NCT02444234: Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
Official title: Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cystic Fibrosis
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2015-05-14
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.

Detailed description: Recent epidemiological studies have demonstrated that the presence of methicillin-resistant Staphylococcus aureus (MRSA) in the airways of patients with CF is associated with more rapid lung function decline and a higher mortality. Tedizolid is a new antibiotic with potent activity against MRSA. Tedizolid is currently FDA approved for treatment of skin soft tissue infections with MRSA. The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with CF.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of CF based on positive sweat chloride or known CF mutation
* Age \> 17 years
* Able to spontaneously expectorate sputum

Exclusion Criteria:

* Any clinically significant laboratory abnormalities
* Presence of an ongoing acute pulmonary exacerbation
* Pregnancy
* Serious past allergy to linezolid or tedizolid
* No alcohol, nicotine, or caffeine-containing products during the study period

Primary outcomes:
measure: Peak Plasma Concentration (Cmax)
timeFrame: 2 days
measure: Area Under the Plasma Concentration Versus Time Curve (AUC)
timeFrame: 2 days
measure: Time to Peak Plasma Concentration (Tmax)
timeFrame: 2 days
measure: Peak Sputum Concentration
timeFrame: 2 days
measure: Area Under the Sputum Concentration Versus Time Curve (AUC)
timeFrame: 2 days
measure: Time to Peak Sputum Concentration (Tmax)
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
References:
Clinical trial NCT01401634: Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hyperglycemia
Keywords: Hyperglycemia Hydration
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2011-07-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Diabetes and high blood sugar are extremely common among patients presenting to US Emergency Departments. Intravenous fluids with or without insulin are often used to treat these patients. However, simple, low-cost interventions, such oral hydration have not been studied in this context. Oral rehydration may be better than no therapy at all, which is often what these patients receive in the first few hours when presenting to busy, overcrowded Emergency Department (ED) with long wait times, or in resource-poor environments such as developing countries. The investigators propose a study to see if oral hydration for adult patients presenting to the ED with high blood sugar i.e. finger-stick (FS) values between 250 and 500 mg/dL can help lower blood sugar at the same rate as intravenous fluids. Half the patients will be given intravenous fluids per our department protocol, while the other half of the patients will be given 2 liters of water to drink over a 1-hour period. Both groups will have their blood sugar measured every 30 mins for 2 hours. The investigators will analyze the data to determine if there is a statistically significant difference in blood sugar between the two groups within 2 hours.


Eligibility criteria: Inclusion Criteria:

* Any patient, above the age of 18 years old, presenting to Emergency Department triage with a fingerstick glucose between 250 and 500 mg/dL

Exclusion Criteria:

* Patients with evidence of DKA (hyperglycemia with ketonuria and abnormal pH or bicarbonate on venous blood gas), HHS, or other critical illnesses requiring immediate medical attention (as determined by ED triage nurses),
* end-stage renal disease requiring dialysis through an arterio-venous shunt or fistula,
* abnormal mental status (GCS \< 15),
* unstable vital signs including pulse \> 100, SBP \< 100, respiratory rate\>20, (or any combination of vital signs not meeting these cutoffs but deemed worrisome by the triage nurse) or unable to tolerate oral intake/actively vomiting.
* Patients who receive IV fluids prior to or during the study period.
* Patients unable to communicate in English or Spanish.
* Jail patients will also be excluded.

Primary outcomes:
measure: Change in Blood Sugar
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of Southern California
state: California
Study officials:
References:
Clinical trial NCT00444834: A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension
Official title: A Phase II, Multi-center, Multiple-dose, Double-blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and an Immediate-Release Carvedilol (IRC) Formulation in Patients With Primary Hypertension
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hypertension
Lead sponsor: Egalet Ltd
Sponsor class: INDUSTRY
First posted: 2007-03-08
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of the Egalet® controlled release formulation to an immediate release Carvedilol tablet.


Eligibility criteria: Inclusion Criteria:

* Have a diagnosis of mild or moderate primary hypertension
* Be able to tolerate a 2 week washout phase followed by a 2 week Placebo run- in phase
* Be minimum 18 years of age

Exclusion Criteria:

* Be intolerant to alfa- or beta-blockers
* Have secondary causes of hypertension
* Be taking more than two antihypertensive medications

Primary outcomes:
measure: The change from baseline to 3 weeks treatment in systolic blood pressure at the end of five minutes of sub-maximal exercise
timeFrame: 15w
Secondary outcomes:
measure: The change in Heart Rate from baseline to 3 weeks treatment measured at the end of five minutes of sub-maximal exercise
timeFrame: 15w
measure: Safety
timeFrame: 15w
Other outcomes:
Locations:
city: Esbjerg
country: Denmark
facility: Site 02
city: Frederiksberg
country: Denmark
facility: Site 01
Study officials:
affiliation: Egalet A/S
name: Christine Andersen, MSc Pharm
role: STUDY_DIRECTOR
References:
Clinical trial NCT03169517: Blood Flow Index as an Indicator of Successful Peripheral Nerve Block
Official title: Blood Flow Index as an Indicator of Successful Peripheral Nerve Block : A Prospective Observational Study Using Laser Speckle Contrast Imaging.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laser
Keywords: Peripheral nerve block
laser speckle contrast imaging
blood flow index
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: One hundred adult patients scheduled for elective upper or lower limb surgery with peripheral nerve block

Brief summary: Laser speckle contrast imaging (LSCI) allows real-time, non-invasive, quantitative measurements of regional blood flow. The aim of this prospective observational study was to evaluate the blood flow changes by LSCI after peripheral nerve block and determine whether this novel optical technique can be used as a reliable indicator of successful blocks.

Detailed description: Methods: One hundred adult patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests before the block and at 5-min intervals till 30 min after the block. The sensitivity, specificity of LSCI as a diagnostic method will be determined by receiver operator characteristic analysis.

Clinical Implications: LSCI with quantitative data could be used as an indicator of successful blocks.

Eligibility criteria: Inclusion Criteria:

* informed consent
* American Society of Anesthesiologists physical statusⅠ-Ⅱ
* Undergo elective upper or lower limb surgery with peripheral nerve block

Exclusion Criteria:

* refusal to participate in the study
* peripheral vascular disease
* digit injury or deficiency
* colored or infected fingernails/toenails
* BMI\>35
* those who had taken vasodilatory drugs before surgery
* preoperative analgesic medications
* Any contraindications to peripheral nerve block such as coagulation abnormalities, allergy to local anaesthetics, peripheral neuropathy.

Primary outcomes:
measure: diagnostic power of LSCI and pinprick sensory tests for predicting successful and failed blocks
timeFrame: at 5-min intervals till 30 min after regional block
Secondary outcomes:
measure: blood flow index
timeFrame: 5 min before regional block and at 5-min intervals till 30 min after regional block
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital
state: Hubei
Study officials:
References:
citation: Wu X, Li J, Joypaul K, Bao WW, Wang D, Huang YJ, Li PC, Mei W. Blood flow index as an indicator of successful sciatic nerve block: a prospective observational study using laser speckle contrast imaging. Br J Anaesth. 2018 Oct;121(4):859-866. doi: 10.1016/j.bja.2018.05.065. Epub 2018 Jul 4.
Clinical trial NCT00525317: Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ?
Official title: Does Oral Magnesium Substitution Relieve Magnesium Induced Leg Cramps ?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cramps
Keywords: Pregnancy
Magnesium
Leg Pain
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Takeda Nycomed
name: Sykehuset Asker og Baerum
First posted: 2007-09-05
Enrollment: 45
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a trial of treatment with tablets containing magnesium for leg cramps in pregnancy.

Detailed description: Healthy pregnant women between 18 and 36 weeks of pregnancy suffering from leg cramps at least twice a week were treated with magnesium tablets or placebo for two weeks, 120 mg x 3 daily.

Eligibility criteria: Inclusion Criteria:

* Pregnant women with recurrent leg cramps (at least twice a week).
* No disease according to helath certificate. Written participation consent must be signed.
* Linguistic ability demanded: Norwegian as the first language. Gestation length more than 17 weeks, less than 36 weeks.

Exclusion Criteria:

* Twin pregnancy.
* Oedema.
* Pre-eclampsia.
* Magnesium supplementation beyond the trial treatment.

Primary outcomes:
measure: Pain intensity and frequency
timeFrame: end of study
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Aker Universituy Hospital
name: Thomas Bohmer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04598217: Is Virtual Reality a Non-pharmacological Premedication?
Official title: The Effect of Virtual Reality on Preoperative Anxiety in Septorhinoplasty Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anxiety
Keywords: Virtual Reality
Anxiety
Premedication
Lead sponsor: Zonguldak Bulent Ecevit University
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients between the ages of 18-65 who will undergo septorhinoplasty surgery

Brief summary: Preoperative anxiety of patients who will undergo septorhinoplasty surgery will be measured and their hemodynamic parameters will be recorded afterwards. Then, a video will be shown to the patients through virtual reality glasses and the effect of this application on their anxiety will be investigated.


Eligibility criteria: Inclusion Criteria:

* ASA I-II risk group
* Will be operated under general anesthesia under elective conditions
* Going to undergo surgery for septoplasty / rhinoplasty
* Patients whose informed consent was read and approved

Exclusion Criteria:

* Those who do not want to participate in the study
* ASA III - IV-V patients
* Psychiatric-Cognitive dysfunction
* Claustrophobia
* Patients using sedative and narcotic drugs
* Alcohol-drug addicts
* Blind or deaf patients
* Patients who cannot speak Turkish

Primary outcomes:
measure: to reduce preoperative anxiety
timeFrame: through study completion, an average of 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zonguldak
country: Turkey
facility: Zonguldak Bülent Ecevit University Medicine Faculty
state: Kozlu
Study officials:
References: